BWA
IONS icon

Basecamp Wealth Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Basecamp Wealth Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.77K Sell
98
-87
-47% -$6.55K ﹤0.01% 1066
2026
Q1 		$13.9K Hold
185
– – ﹤0.01% 931
2025
Q4 		$14.6K Buy
+185
New +$13.9K ﹤0.01% 873

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Basecamp Wealth Advisors's IONS Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 47% in Q2 2026, selling an estimated $6.55K and leaving 98 shares worth $7.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

Basecamp Wealth Advisors first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. The position peaked at $14.6K in Q4 2025. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Basecamp Wealth Advisors held 98 shares of Ionis Pharmaceuticals worth $7.77K as of Q2 2026.
  • Basecamp Wealth Advisors sold 87 Ionis Pharmaceuticals shares in Q2 2026, an estimated $6.55K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1066 holding.
  • Basecamp Wealth Advisors first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Ionis Pharmaceuticals position peaked at $14.6K in Q4 2025.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.